Ignite Creation Date:
2025-12-24 @ 7:08 PM
Ignite Modification Date:
2026-04-18 @ 8:41 PM
Study NCT ID:
NCT05927857
Status:
RECRUITING
Last Update Posted:
2025-08-22
First Post:
2023-06-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Sponsor:
National Health Research Institutes, Taiwan
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
T1223
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None